Drug Development: Illuminating the Druggable Genome

Mar 14, 2017
RFA-RM-16-024, RFA-RM-16-025, & RFA-RM-16-026

Illuminating the Druggable Genome: Implementation Phase

The goal of the Illuminating the Druggable Genome (IDG) Program is to improve our understanding of the properties and functions of proteins that are currently not well studied within commonly drug-targeted protein families.

Currently, the pilot phase of the program is developing a website that integrates information about understudied proteins so that researchers everywhere can easily access it, catalyzing their own research and helping them find new proteins that may be of interest. In addition IDG is developing technologies to enable the study of understudied druggable proteins in a high throughput manner.  

The upcoming implementation phase of IDG aims to expand the informatics tools developed in the pilot phase, elucidate the function of understudied proteins from three key druggable protein families, and disseminate the IDG-generated resources to the greater scientific community.


  • Pre-Application Submission: Feb. 14, 2017
  • Application Submission: 5:00 PM local time of applicant organization, Mar. 14, 2017

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.